Differential Chemoproteomics Reveals MARK2/3 as Cell Migration‐Relevant Targets of the ALK Inhibitor Brigatinib
Authors:
- 4 May 2023
- journal article
- research article
- Published by Wiley in ChemBioChem
- Vol. 24 (11) , e202200766
Abstract
Metastasis poses a major challenge in cancer management, including EML4‐ALK‐rearranged non‐small cell lung cancer (NSCLC). As cell migration is a critical step during metastasis, we assessed the anti‐migratory activities of several clinical ALK inhibitors in NSCLC cells and observed differential anti‐migratory capabilities despite similar ALK inhibition, with brigatinib displaying superior anti‐migratory effects over other ALK inhibitors. Applying an unbiased in situ mass spectrometry‐based chemoproteomics approach, we determined the proteome‐wide target profile of brigatinib in EML4‐ALK+ NSCLC cells. Dose‐dependent and cross‐competitive chemoproteomics suggested MARK2 and MARK3 as relevant brigatinib kinase targets. Functional validation showed that combined pharmacological inhibition or genetic modulation of MARK2/3 inhibited cell migration. Consistently, brigatinib treatment induced inhibitory YAP1 phosphorylation downstream of MARK2/3. Collectively, our data suggest that brigatinib exhibits unusual cross‐phenotype polypharmacology as, despite similar efficacy for inhibiting EML4‐ALK‐dependent cell proliferation as other ALK inhibitors, it more effectively prevented migration of NSCLC cells due to co‐targeting of MARK2/3.Keywords
Funding Information
- National Cancer Institute (P30-CA076292)
- Florida Department of Health (09BE-04)
This publication has 31 references indexed in Scilit:
- Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 MutationsNew England Journal of Medicine, 2012
- Phosphorylation of CRTC3 by the salt-inducible kinases controls the interconversion of classically activated and regulatory macrophagesProceedings of the National Academy of Sciences, 2012
- Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivityNature Biotechnology, 2011
- Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid CancerJournal of Clinical Oncology, 2011
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung CancerNew England Journal of Medicine, 2010
- Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanomaNature, 2010
- Cellular functions of FAK kinases: insight into molecular mechanisms and novel functionsJournal of Cell Science, 2010
- Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancerNature, 2007
- Discovery of N-(2-Chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a Dual Src/Abl Kinase Inhibitor with Potent Antitumor Activity in Preclinical AssaysJournal of Medicinal Chemistry, 2004
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004